Growing Competition for the World’s Most Profitable Drug as Multiple New Adalimumab Biosimilars Launch
By EsqSocial Corporation 11/05/21
During the first quarter of 2021, multiple companies launched adalimumab biosimilars as a growing number of biosimilar players marketed their versions of the world’s most profitable drug, Humira®, which had sales of about $20 billion in 2020. While none have launched thus far, at least eight adalimumab biosimilars are due to launch by the end of 2023 in the United States, where Abbvie secured over $16 billion of its Humira® sales revenues in 2020....
By: Rothwell, Figg, Ernst & Manbeck, P.C.